Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/30/2025

Transarterial Chemoembolization for Liver Tumors

Procedure Overview

  • The American College of Radiology and the National Comprehensive Cancer Network recommend that TACE be performed by interventional radiologists who selectively catheterize the arterial branch of the hepatic artery feeding the tumor through a femoral artery access in the groin 1, 3
  • The procedure exploits the dual blood supply to the liver, where liver tumors are primarily supplied by the hepatic artery, making selective arterial delivery highly effective 4, 3

Types of TACE

  • Conventional TACE (cTACE) uses a mixture of an oil-based contrast agent and chemotherapeutic agents, followed by embolization with gelfoam particles, as recommended by the Clinical and Molecular Hepatology guidelines 1
  • Drug-eluting bead TACE (DEB-TACE) uses microspheres loaded with chemotherapeutic agents that simultaneously deliver the drug and cause embolization, potentially reducing systemic drug exposure 1

Patient Selection

  • The Barcelona Clinic Liver Cancer (BCLC) staging system recommends TACE as the standard first-line treatment for intermediate-stage HCC, with the goal of delaying tumor progression and providing survival benefits 5
  • TACE is recommended for patients with preserved liver function, good performance status, and no radiologic evidence of vascular invasion or extrahepatic spread when surgical resection, transplantation, or ablation are not viable options, according to the Clinical and Molecular Hepatology guidelines 2, 8

Contraindications and Cautions

  • The Journal of Hepatology guidelines list absolute contraindications for TACE, including decompensated liver disease, advanced liver dysfunction, main portal vein occlusion, and obstructive jaundice 2, 5

Effectiveness and Outcomes

  • TACE has been proven to delay tumor progression, prevent macrovascular invasion, and provide survival benefits compared to supportive care, with median survival for intermediate HCC cases extended from approximately 16 months to about 20 months, according to the Journal of Hepatology guidelines 5

Follow-up and Assessment

  • Post-procedure imaging (CT or MRI) is essential to evaluate tumor response using modified Response Evaluation Criteria in Solid Tumors (mRECIST), as recommended by the Clinical and Molecular Hepatology guidelines 2, 6